Outcome of Board Meeting held today i.e., 15-05-2025
Awaiting price reaction for this filing.
The Board of Sarda Proteins Ltd met on 15 May 2025 and approved the audited financial results for Q4 and FY ended 31 March 2025. Total income surged to Rs 2,419.17 lakhs in FY25 from Rs 146.11 lakhs in FY24, driven by an explosive jump in revenue from operations. However, profit before tax was almost flat at Rs 2.02 lakhs versus Rs 1.89 lakhs, and FY25 PAT actually fell to Rs 0.51 lakhs from Rs 1.94 lakhs. Q4 FY25 standalone results slipped into a loss of Rs 11.23 lakhs at the PAT level, compared to a profit of Rs 2.01 lakhs in Q4 FY24. Statutory auditor S K Agarwal & Associates issued an unmodified opinion, confirmed by the CFO. The Board also appointed Krina Gokulkumar Shah as Secretarial Auditor for FY 2025-26.
Massive top-line growth has not translated into earnings — margins have compressed sharply, Q4 turned into a loss, and operating cash flows remain negative. For shareholders, this is a red flag on profitability despite scale, and the stock may react negatively unless the company demonstrates a path to convert revenue into real profits.